ERBB2 and neoplasm: Furthermore, the prolonged exposure of gastric neoplasms to trastuzumab-based regimens favors the temporal loss of HER2 overexpression, and the concomitant upregulation of bypass signaling circuits sustaining tumor cell proliferation and survival (e.g., EGFR and c-Met-mediated signaling) [24].